Protocols
ALEXION-ALXN1210-TMA-313 Phase III OPEN TO ACCRUAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
ALLOVIR-P-106-001-RESP Phase I/II OPEN TO ACCRUAL *
Phase 1-2, double-Blind, Placebo-controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to standard of Care for the Treatment of High-Risk patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
JNJ-68284528MMY2005-OOS Phase II OPEN TO ACCRUAL *
A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients with MM
SYNDAX-SNDX-6352-0504-CGVHD Phase II OPEN TO ACCRUAL
AGAVE-201, A Phase 2, open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patient with Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy